Atrion Corporation Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/16/2024)
| Balance Sheet | Total Assets | 260,825,000.00 | ROE | – |
| Balance Sheet | Total Equity | 242,889,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -28,172,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -2,313,000.00 | – | – |
| Cashflow | Operating Cash Flow | 20,006,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 11.02 | Div. Yield | – |
| Income | Net Income | 19,411,000.00 | P/E | – |
| Income | Shares Outstanding | 1,761,000.00 | P/B | – |
| Income | Total Revenue | 168,597,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Atrion Corporation (Atrion), and its subsidiaries, develop and manufacture products, primarily for medical applications. The Company´s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. During the year ended December 31, 2011, the Company´s fluid delivery products accounted for 38% of the Company´s revenues. These products include valves that promote infection control and needle safety. The Company has developed a variety of luer syringe check valves and one-way valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, catheter and other applications. The Company also makes tubing clamps in a variety of materials and colors that are compatible with various grades of tubing and sterilization processes, and produce specialized intravenous sets for use in numerous applications, including anesthesia and oncology.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.atrioncorp.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more